Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
20.46
+0.52 (2.61%)
Nov 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 19.59 - 20.50
52 week 11.20 - 24.97
Open 20.00
Vol / Avg. 2.33M/1.80M
Mkt cap 7.11B
P/E 4.09
Div/yield     -
EPS 5.00
Shares 347.33M
Beta -0.85
Inst. own 81%
Nov 29, 2017
Valeant Pharmaceuticals International Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - 11:00AM EST - Add to calendar
Nov 14, 2017
Valeant Pharmaceuticals International Inc at Stifel Healthcare Conference - Webcast
Nov 7, 2017
Q3 2017 Valeant Pharmaceuticals International Inc Earnings Release
Nov 7, 2017
Q3 2017 Valeant Pharmaceuticals International Inc Earnings Call - Webcast
Oct 4, 2017
Valeant Pharmaceuticals International Inc at Deutsche Bank Leveraged Finance Conference - Webcast
Sep 25, 2017
Valeant Pharmaceuticals International Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
Sep 12, 2017
Valeant Pharmaceuticals International Inc at Morgan Stanley Healthcare Conference - Webcast
  

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 58.58% -24.89%
Operating margin 1.67% -5.85%
EBITD margin - 41.49%
Return on average assets 12.76% -5.21%
Return on average equity 112.73% -53.16%
Employees 21,500 -
CDP Score - D

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 61
Paul S. Herendeen Chief Financial Officer, Executive Vice President
Age: 61
Christina Ackermann Executive Vice President, General Counsel
Age: 52
Thomas J. Appio Executive Vice President, Company Group Chairman, International
Age: 55
William D. Humphries Executive Vice President, Company Group Chairman, Dermatology
Age: 50
Thomas W. Ross Sr Lead Independent Director
Age: 66
Richard U. DeSchutter Independent Director
Age: 76
Fredric N. Eshelman Pharm.D., Ph.D. Independent Director
Age: 68
D. Robert Hale Independent Director
Age: 32
Argeris N. Karabelas Ph.D. Independent Director
Age: 64